An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery

Journal of Pharmaceutical Sciences

Volumn 94, Issue 10, 2005, Pages 2327-2343

  Parrott, Neil ^a   Paquereau, Nicolas ^a   Coassolo, Philippe ^a   Lavé, Thierry ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Absorption; Computational ADME; Drug discovery; GastroPlus; Pharmacokinetics; Physiological model; Simulations

Indexed keywords

GENERIC DRUG; NEW DRUG;

ANIMAL CELL; ARTICLE; ARTIFICIAL MEMBRANE; BIOAVAILABILITY; BLOOD SAMPLING; DRUG RESEARCH; DRUG SCREENING; DRUG UTILIZATION; LIVER CELL; MEMBRANE PERMEABILITY; MODEL; NONHUMAN; PLASMA CLEARANCE; PREDICTION; PROTEIN BINDING; RAT; SOLUBILITY; SOLUBILIZATION;

EID: 27944458924     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20419     Document Type: Article

References (45)

1. Norris DA, Leesman GD, Sinko PJ, Grass GM. 2000. Development of predictive pharmacokinetic Simulation models for drug discovery. J Control Rel 65:55-62.
2. Theil F, Haddad S, Guentert T, Poulin P. 2003. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett 138:29-49.
3. Boobis A, Gundert-Remy U, Kremers P, Macheras P, Pelkonen O. 2002. In silica prediction of ADME and pharmacokinetics: Report of an expert meeting organised by COST B15. Eur J Pharm Sci 17:183-193.
4. Leahy DE. 2004. Drug discovery information integration: Virtual humans for pharmacokinetics. DDT: BIOSILICO 2:79-84.
5. Grass GM, Sinko PJ. 2002. Physiologically-based pharmacokinetic simulation modelling. Adv Drug Deliv Rev 54:433-451.
6. Jones H, Lave T. 2003. Comparison of empirical and physiologically-based approaches for the prediction of human pharmacokinetics. Postdoc report.
7. Parrott N, Jones H, Paquereau N, Lave T. 2005. Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. Basic Clin Pharmacol Toxicol 96:193-199.
8. Poulin P, Theil F. 2002. Prediction of pharmacokinetics prior to in vivo studies II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 91:1358-1370.
9. Poulin P, Theil F. 2000. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 89: 16-35.
10. Poulin P, Theil F. 2001. Prediction of adipose tissue:plasma partition coefficients for structurally unrelated drugs. J Pharm Sci 90:436-447.
11. Nestorov I. 2003. Whole body pharmacokinetic models. Clin Pharmacokinet 42:883-908.
12. Hoang K-CT. 1995. Physiologically based pharmacokinetic models: Mathematical fundamentals and simulation implementations. Toxicol Lett 79:99-106.
13. Houston JB. 1994. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
14. Pang KS, Rowland M. 1977. Hepatic clearance of drugs. 1: Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653.
15. Agoram B, Woltosz WS, Bolger MB. 2001. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 50:S41-S67.
16. Hasselbalch KA. 1916. Die Berechnung der Wasserstoffzahl des Blutes aus der freien und gebunden Kohlensäure desselben, und die Sauerstoffbindung des Blutes als Funktion der Wasserstoffzahl. Die Biochem 78:112-144.
17. Noyes AS, Whitney WR. 1897. The rate of solution of solid substances in their own solutions. J Am Chem Soc 19:930-934.
18. Meylan WM, Howard PH. 1995. Atom/fragment contribution method for estimating octanol-water partition coefficients. J Pharm Sci 84: 83-92.
19. Kansy M, Senner F, Gubernator K. 1998. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption process. J Med Chem 41:1007-1010.
20. Kansy M, Avdeef A, Fischer H. 2004. Advances in screening for membrane permeability: High-resolution PAMPA for medicinal chemists. Drug Discov Today: Technol 1:349-355.
21. Mithani SD, Bakatselou V, TenHoor CN, Dressman JB. 1996. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm Res 13:163-167.
22. Dressman JB, G.L A, Reppas C, Shah VP. 1998. Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm Res 15:11-22.
23. Zwart LLd, Rompelberg CJM, Sips AJAM, Welink J, Engelen JGMv. 1999. Anatomical and physiological differences between various species used in studies on the pharmacokinetics and toxicology of xenobiotics. A review of literature. Rijksinstitute voor Volksgezondheit en Milieu RIVM report 623860 010.
24. Zuegge J, Schneider G, Coassolo P, Lave T. 2001. Prediction of hepatic metabolic clearance: Comparison and assessment of prediction models. Clin Pharmacokinet 40:553-563.
25. Poulin P, Theil F. 2002. Prediction of pharmacokinetics prior to in vivo studies I. Mechanism-based prediction of volume of distribution. J Pharm Sci 91:129-156.
26. Parrott N, Lave T. 2002. Prediction of intestinal absorption: Comparative assessment of GASTRO-PLUS and IDEA. Eur J Pharm Sci 17:51-61.
27. Wenlock MC, Austin RP, Barton P, Davis AM, Leeson PD. 2003. A comparison of physiochemical property profiles of development and marketed oral drugs. J Med Chem 46:1250-1256.
28. Yata N, Toyoda T, Murakami T, Nishiura A, Higashi Y. 1990. Phosphatidylserine as a determinant for the tissue distribution of weakly basic drugs in rats. Pharm Res 7:1019-1025.
29. Suzuki T, Kato Y, Sasabe H, Itose M, Miyamoto G, Sugiyama Y. 2002. Mechanism for the tissue distribution of grepafloxacin, a fluoroquinolone antibiotic, in rats. Drug Metab Dispos 30:1393-1399.
30. Lobell M, Sivarajah V. 2003. In silico prediction of aqueous solubility, human plasma protein binding and volume of distribution of compounds from calculated pKa and AlogP98 values. Molec Diversity 7:69-87.
31. Raub TJ, Barsuhn CL, Williams LR, Decker DE, Sawada GA, Ho NF. 1993. Use of a biophysical-kinetic model to understand the roles of protein binding and membrane partitioning on passive diffusion of highly lipophilic molecules across cellular barriers. J Drug Targeting 1:269-286.
32. Sawada GA, Barsuhn CL, Lutzke BS, Houghton ME, Padbury GE, Ho NFH, Raub TJ. 1999. Increased lipophilicity and subsequent cell partitioning decrease passive transcellular diffusion of novel, highly lipophilic antioxidants. J Pharmacol Exp Ther 288:1317-1326.
33. Camenisch G, Alsenz J, Waterbeemd Hvd, Folkers G. 1998. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur J Pharm Sci 6:313-319.
34. Berezhkovskiy LM. 2003. Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics. J Pharm Sci 93:364-374.
35. Kawai R, Lemaire M, Steimer J-L, Bruelisauer A, Niederberger W, Rowland M. 1994. Physiology based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. J Pharmacokinet Biopharm 22:327-365.
36. Levitt DG. 2002. PKQuest: Capillary permeability limitation and plasma protein binding-application to human inulin, dicloxacillin, and ceftriaxone pharmacokinetics. BMC Clin Pharmacol 2:7.
37. Ebling W, Wada F, Russell D, R SD. 1994. From piecewise to full physiologic pharmacokinetic modeling: Applied to thiopental disposition in the rat. J Pharmacokinet Biopharmaceutics 22:259-292.
38. Bjoerkman S, Stanski DR, Harashima H, Dowrie R, Harapat SR, Wada DR, Ebling WF. 1993. Tissue distribution of fentanyl and alfentanil in the rat cannot be described by a blood flow limited model. J Pharmacokinetics Biopharm 21:255-279.
39. Schmitt W, Willmann S. 2004. Physiology-based pharmacokinetic modeling: Ready to be used. Drug Disc Today Technol 1:449-456.
40. Levitt D. 2002. PKQuest: A general physiologically based pharmacokinetic model. Introduction and application to propranolol. BMC Clin Pharmacol 2:5.
41. Galia E, Nicolaides E, Hoerter D, Loebenburg R, Reppas C, Dressman JB. 1998. Evaluation of various dissolution media for predicting in vivo performance of class I and class II drugs. Pharm Res 15:698-705.
42. Nicolaides E, Symillides M, Dressman JB, Reppas C. 2001. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm Res 18:380-388.
43. Wohnsland F, Faller B. 2001. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem 44:923-930.
44. Bergström CAS, Luthman K, Artursson P. 2004. Accuracy of calculated pH-dependent aqueous drug solubility. Eur J Pharmaceut Sci 22:387-398.
45. Rowland M, Balant L, Peck C. 2004. Physiologically based pharmacokinetics in drug development and regulatory science: A workshop report. AAPS Pharm Sci 6:E6.